Stoke Therapeutics Adds Rare Disease Commercialization Veteran to Board Ahead of Key FDA Decision
Event summary
- Stoke Therapeutics appointed Bo Cumbo to its board of directors, replacing Edward Kaye, M.D., who retired after serving since 2017.
- Cumbo brings 30 years of biopharmaceutical experience, including commercial leadership roles at Sarepta Therapeutics and Solid Biosciences.
- Zorevunersen, Stoke's lead candidate for Dravet syndrome, is targeting a potential FDA approval in early 2028.
- Stoke has a strategic collaboration with Biogen for global commercialization rights outside the U.S., Canada, and Mexico.
The big picture
Stoke's board appointment reflects a strategic pivot toward commercialization expertise as it nears a critical FDA decision for zorevunersen. The move underscores the growing importance of rare disease commercialization experience in biotech governance, particularly for companies with near-term regulatory milestones. With Biogen as a global partner, Stoke is positioning itself for potential scale in the Dravet syndrome market, which affects an estimated 38,000 patients across key regions.
What we're watching
- Commercialization Readiness
- How Bo Cumbo's experience will shape Stoke's preparation for zorevunersen's potential launch in 2028.
- Regulatory Momentum
- The pace at which zorevunersen advances through Phase 3 trials and secures FDA approval.
- Pipeline Expansion
- Whether Stoke can leverage its TANGO platform to address other severe genetic diseases beyond Dravet syndrome.
Related topics